



Insights: Publications

Elutia Founder and CEO Offers Insight on Kilpatrick Townsend's Impactful Guidance

September 27, 2023

Kilpatrick Townsend is proud to have provided counsel to **Elutia** in its rebrand to reflect its strategic focus on drug eluting biomatrices.

Elutia Founder and CEO **C. Randal Mills, Ph.D.** says, "In September, our company accomplished three key milestones:

- 1) We rebranded as Elutia to reflect our strategic focus on drug eluting biomatrix technology,
- 2) sold our Orthobiologics Business Unit, and
- 3) closed a private placement for proceeds up to \$26M.

Each of these major corporate events would not have been possible without the help from the dedicated team at Kilpatrick Townsend & Stockton LLP.

Led by **Michael "Mick" Cochran**, **David M. Eaton**, **Agnes Trenche Mora**, **Catherine Zhu**, and **Paige Clifton**, we received the highest level of legal support and counsel to help guide us through each of these complex announcements. I am personally appreciative of Kilpatrick's unparalleled commitment and professionalism. We look towards continuing our relationship as our company executes on future milestones."

Related People



Michael J. Cochran

t 404.815.6307

mcochran@ktslaw.com



David M. Eaton

t 415.273.4324

deaton@ktslaw.com



Catherine E. Zhu

t 404.532.6966

cezhu@ktslaw.com



Paige N. Clifton

t 404.815.6089

pclifton@ktslaw.com